Cirmtuzumab (also UC-961) is an anti-ROR1 humanised monoclonal antibody.

It is an experimental drug in early-stage clinical trials for various cancers including chronic lymphocytic leukemia (CLL).

References


Cirmtuzumab Semantic Scholar

BristolMyers Squibb Krebsimmuntherapie gibt USPharmakonzern Schub

Neues Protokoll für das HCC

Cirmtuzumab Semantic Scholar

Cirmtuzumab as monotherapy was assessed in a Download Scientific Diagram